5 Gobin P, Lemaitre F, Marchand S et al. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatographytandem mass spectrometry. Antimicrob Agents Chemother 2010; 54: 1941-8. Salvage treatment of methicillinresistant staphylococcal endocarditis with ceftaroline: a multicentre observational study Sir, b-Lactam agents have been the main antibacterial agents used for the treatment of infective endocarditis since the discovery of penicillin more than 70 years ago. Indeed, due to their bactericidal activity and a safety profile that allows the use of high doses, this class represents the backbone of most first-line regimens in this indication. 1 However, no b-lactam effective against methicillin-resistant staphylococci was available until recently, and the use of antibacterial agents recommended in these settings (mostly vancomycin and daptomycin) may be limited by dose-dependent toxicity and/or the emergence of resistance. Ceftaroline is a new cephalosporin agent with in vitro and in vivo activity against methicillin-resistant staphylococci, with MIC 90 s of 0.5 and 1 mg/L for methicillin-resistant coagulase-negative 2 It has been approved by the regulatory agencies in the USA (FDA) and the European Union (EMEA) for the treatment of complicated acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired pneumonia (CAP), based on four pivotal randomized clinical trials. 3 However, its pharmacokinetic and pharmacodynamic characteristics make it a potential alternative for the salvage treatment of complicated infective endocarditis. Experiments with various MRSA strains in a model of aortic valve endocarditis in rabbits have been promising. 4, 5 Case reports and small series of ceftaroline use for the salvage treatment of endocarditis due to methicillinresistant staphylococci in humans have been reported, 6 -10 but additional information is needed given that: (i) sample sizes have been limited (total of 20 cases reported as of December 2013); (ii) publication bias is a concern (cases with favourable outcomes are most likely to be reported and selected for publication); and (iii) all cases published to date have been due to MRSA, where ceftaroline may be an alternative for the salvage treatment of MRCoNS endocarditis as well. We report a series of eight consecutive observations of ceftaroline use as salvage treatment for methicillin-resistant staphylococcal endocarditis following its introduction in France in 2013.
Cases were identified through the French Infectious Diseases Society (Société de Pathologie Infectieuse de Langue Française, SPILF) discussion list, containing 600 clinicians and biologists. Only patients who fulfilled the Duke criteria for definite infective endocarditis and who received ceftaroline as salvage treatment for .48 h were enrolled. Data were collected by the physicians in charge through an anonymous standardized questionnaire. The characteristics of these eight observations are presented in Table 1 . Briefly, the observations were on four females and four males, with a median age of 73.5 years (range 33 -85). All cases were left-sided endocarditis, with or without right-sided involvement, four were prosthetic valve endocarditis, three had perivalvular abscess and seven had vegetations (size range 5 -25 mm). Five cases were due to MRSA and three to MRCoNS. Ceftaroline was introduced as salvage treatment because of clinical failure (n ¼4), microbiological failure (n¼ 2) and worsening of valvular lesions under first-line regimens (n¼ 4), with intolerance to alternative agents in three cases. Previous antistaphylococcal treatments were mostly vancomycin (n ¼ 5), daptomycin (n ¼ 5), in combination with gentamicin (n¼ 6), and/or rifampicin (n¼ 2). Ceftaroline was prescribed for a median duration of 13 days (range 5 -42), with dosages ranging from 400 mg twice daily to 800 mg three times daily. No side effects were reported. The final outcome was classified as 'cure' in five cases, with a median follow-up of 115 days after ceftaroline discontinuation, and 'failure' in three cases (i.e. palliative care with lifelong suppressive antibacterial agent in one case and endocarditis-related death in two cases).
To the best of our knowledge, this is the second largest series on the use of ceftaroline for the salvage treatment of endocarditis due to methicillin-resistant staphylococci reported to date, and the first that has enrolled patients with MRCoNS endocarditis. Previous observations on the use of ceftaroline for salvage treatment of MRSA endocarditis suggested that the tolerability of this agent is good at high doses (i.e. most frequently 600 mg three times daily for endocarditis, compared with 600 mg twice daily for ABSSSI or CAP) and patients were classified as 'clinical cure' in 18 of the 20 cases reported to date (90%). In conclusion, ceftaroline appears to be well tolerated as a salvage treatment of methicillin-resistant staphylococcal endocarditis, at higher doses than recommended for CAP or ABSSSI. Data available to date do not allow a firm conclusion regarding its efficacy in humans in this indication. Further improvement could arise from: (i) larger international observational studies; (ii) advances in therapeutic drug monitoring, which may allow the use of higher doses, as recommended for most b-lactams indicated for the treatment of endocarditis; and (iii) randomized clinical trials, although these are particularly difficult to set up in the field of endocarditis.
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